Fibrosis inhibitor
AssigneeStelic Institute of Regenerative Medicine, Stelic Institute & Co.
InventorsHIROYUKI YONEYAMA, Yoshiro Kai, Hideki Tagashira, Jun Koyama
Life of this patent
Estimating the term…
Abstract
An objective of the present invention is to provide methods for treating or preventing fibrotic diseases, which are based on the novel finding that fibrosis is suppressed by administering ER-TR7 to a subject.
Claims14
A fibrosis-suppressing agent comprising ER-TR7 or a functionally equivalent substance as an active ingredient.
A method for producing a fibrosis-suppressing agent comprising as an active ingredient an antibody, which comprises the step of preparing the antibody using an ER-TR7 antigen.
(canceled)
A method of modulating fibrosis in a subject, comprising the steps of:
- diagnosing a subject with tissue fibrosis;
- and
- administering to the subject a therapeutically effective amount of a formulation comprised of a pharmaceutically acceptable carrier and an antibody that binds an ER-TR7 antigen protein.
Dependencies are inferred from the claim text.